VCYT Q2 2021 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+166.2% YoY

Gross Profit

$38M68.3% margin

Operating Income

-$7M-13.6% margin

Net Income

-$9M-16.4% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+50.1%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$360,000

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$56M

Stockholders' Equity

$971M

Cash & Equivalents

$328M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$21M	+166.2%
Gross Profit	$38M	$13M	+188.4%
Operating Income	-$7M	-$11M	+32.4%
Net Income	-$9M	-$11M	+18.0%

Revenue Segments

Product

$3M62%

Biopharmaceutical

$2M38%